Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. - Wikidata - wikimedia - TriplyDB

Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

http://www.wikidata.org/entity/Q36933000

about

Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.Oropharyngeal candidiasis in the era of antiretroviral therapy Novel FKS mutations associated with echinocandin resistance in Candida species.Peptide-based Antifungal Therapies against Emerging Infections.Breakthrough invasive candidiasis in patients on micafungin.Screening for drug-resistant Candida yeasts with chromogenic agar.Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.Canadian clinical practice guidelines for invasive candidiasis in adults.Biochemical characterization of an anti-Candida factor produced by Enterococcus faecalis Genomics-driven discovery of the pneumocandin biosynthetic gene cluster in the fungus Glarea lozoyensis.FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.Micafungin in the treatment of invasive candidiasis and invasive aspergillosis The susceptibility patterns of Candida species isolated from urine samples to posaconazole and caspofungin.Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.Echinocandin Resistance in Candida.Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance.Current perspectives on echinocandin class drugs.Caspofungin: when and how? The microbiologist's view.Anidulafungin: when and how? The clinician's view.Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis.Mechanisms of echinocandin antifungal drug resistance.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus.Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.Echinocandin Resistance in Candida Species: a Review of Recent Developments.Caspofungin MIC Distribution amongst Commonly Isolated Candida Species in a Tertiary Care Centre - An Indian Experience.Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi.Echinocandins in antifungal pharmacotherapy.Phenotypic analysis of a family of transcriptional regulators, the zinc cluster proteins, in the human fungal pathogen Candida glabrata.

P2860

Q33676430-6AE9FF37-BC22-4FF1-B301-157B86623CAE Q33746435-2A720D6D-091C-417A-801B-84A5331F4B85 Q33826330-A6A93FBA-17EC-4314-81B6-DEB8470EBB8E Q33862289-04687D59-F761-4142-9932-DD6B57FDABAC Q33963538-DC7059C6-3063-499D-B0B1-A18F2C8E9CD3 Q34009338-35E940C5-1F33-4736-90CA-E31F9C2F3728 Q34058099-4E46BAEF-C98B-4AFA-B364-79DFB682AFB6 Q34237335-68E8DFD5-FEBF-4C45-BA8B-6B0487BE07F8 Q34325020-09B77CF9-5CE9-476E-822B-B1BE1F4C06A9 Q34729062-2AABD0F3-9A85-4D2B-B049-F076821725E3 Q34737334-8A6BD02F-95C9-4FAE-B7EA-19A820E8EA17 Q35026516-8978CAA1-E5CA-4182-8FEF-5A2631270039 Q35276302-2A7A7772-0013-496E-BAEE-AD7694E59758 Q35635472-BF8FE793-2AE0-435B-B1CD-B6C68B73349F Q35806170-579A6B7D-B4E3-4FB7-A0DA-EF3C74556930 Q35867789-01C72DE0-D0FB-440D-9FD6-B50B08E96004 Q36018829-5C848168-55AB-4C92-994B-0B20E4C6071B Q36172500-2AE62DBC-751B-4EC9-A2BB-80E82D5F0A32 Q36276186-3B710D7F-C30D-467C-B42E-75E7E8CEBEAF Q36364100-7217AAAB-DAC1-4B28-A9FE-8C2A4BBF83B9 Q36856930-48CC01B6-927F-4BA5-A352-B09BBE24DA66 Q37124005-41C324A9-09C8-49EE-975E-B05FC60DF18F Q37335747-18AE16EB-6634-40DC-BA70-82C36ABACDCC Q37381931-4BE35337-C2C2-4297-9DF9-109F54F447DC Q37528498-48029BC7-956F-4616-9491-B8DB418A8CB7 Q37554055-69F98B9E-BD46-4DBE-B584-1F284C699B6A Q37888750-681BD84D-FE68-47B8-80C2-9B4416631B5B Q37888751-DE486DAA-3319-438E-A88C-0D948A820E18 Q38027469-9E8B0BAA-E001-4E89-BBD9-C27730405636 Q38254290-045E4B99-F5BF-427F-8231-7DA9C19FE3AF Q38531765-2E515CB1-B319-4894-908E-72F815781268 Q38550402-76327901-ADA5-438B-912D-0E5BAC527B51 Q38586680-565FAE3D-E74B-4334-B337-8459A0D1277E Q38711698-C957E70F-A1A4-452A-94F0-C9D7CB5597BD Q38916677-C3B94EDE-CA17-4322-8F1B-BC397E816179 Q38988521-1669C10B-AE61-4C63-AB98-2DA36089009B Q39041926-05AAD308-5239-480A-8B91-59728DCD5900 Q39338332-A9D85D79-95B8-43B4-A5FF-A2ECD9924634 Q39458862-731E2EA8-4458-4F96-87A3-3766BACAF1B8 Q39726491-81414F93-328E-43A4-BA18-340F5C3249B7

P2860

Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

http://www.wikidata.org/entity/Q36933000

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Development of caspofungin res ...... to Candida glabrata infection.

@en

type

label

Development of caspofungin res ...... to Candida glabrata infection.

@en

prefLabel

Development of caspofungin res ...... to Candida glabrata infection.

@en

P1433

Q36933000-C1CA6EE2-B5F3-4C83-97E5-294F92F31B6E

P1476

Q36933000-8D18DDB8-F458-4453-A773-2CE691C327BF

P2093

Q36933000-4E64D284-7578-44C4-BE47-D8025B2C0630

Q36933000-BE7C38C1-D9B8-4C8F-BF5A-A9D72F8D4409

Q36933000-C616AF21-9478-4ED6-8D43-DDE1F5C2D4FC

Q36933000-CA8B01D3-E40A-4A92-A7DB-F38C0FA71136

Q36933000-E7CD4B2B-078F-49F1-86DB-B5BB169C3E12

P2860

Q36933000-0A57F21C-8836-40EE-A98B-F3568CD9EB08

Q36933000-0EBEDD98-887E-4FBF-A5A1-D300EE5182FB

Q36933000-0F274338-C90D-46FC-A31B-AA2CAF0D559B

Q36933000-2CD05CE2-43C3-4ED6-BAE3-9925F30C7F04

Q36933000-2ED8B1B7-6BB9-4A51-82F3-8D928E8B6FE9

Q36933000-370E50FA-3AA3-4207-9216-810AFDC1972B

Q36933000-479B3C88-CA19-42C5-8E91-1E6309853154

Q36933000-6185BECE-8477-4719-90E0-614DE17D4748

Q36933000-660CA92A-2853-4BDE-B766-8A6660C57D90

Q36933000-6F5CA485-5CA0-40FD-B4A9-34E8CAE04B45

P304

Q36933000-5A2976B5-356B-4AB8-AC3A-3235486DB727

P31

Q36933000-745B753A-B26C-4A11-9ACB-7DBD08CCE1F1

P356

Q36933000-C6D1646C-BED4-4B93-B0A7-1B64EE5AF949

P407

Q36933000-ABB4E752-AFD4-4E8E-BA63-1F3DBD14D647

P433

Q36933000-07E48A2F-3F54-45EE-9643-4461DAC3ABC8

P478

Q36933000-BBEB826E-D84A-4C76-9B1D-184A5777B0D8

P50

Q36933000-CE490B81-625F-4129-B9E9-D930B5652B19

P577

Q36933000-F7B1C86A-60E4-48AF-A924-CBF24FE530C4

P698

Q36933000-8E5E42DC-734D-4825-8878-ABED11DFA723

P921

Q36933000-B14E8D76-12DE-47A4-B0EF-1463028ADCC4

P932

Q36933000-328FCFB2-A46E-418A-AC7B-D3673EBF1DD1

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Development of caspofungin res ...... to Candida glabrata infection

@en

P2093

Ana C Vallor

http://www.w3.org/2001/XMLSchema#string

George R Thompson

http://www.w3.org/2001/XMLSchema#string

James S Lewis

http://www.w3.org/2001/XMLSchema#string

Nyria C Villareal

http://www.w3.org/2001/XMLSchema#string

Thomas F Patterson

http://www.w3.org/2001/XMLSchema#string

P2860

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.

Anidulafungin versus fluconazole for invasive candidiasis.

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.

Serum differentially alters the antifungal properties of echinocandin drugs.

Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature.

Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.

P304

3783-3785

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00473-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Nathan P. Wiederhold

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18676885

http://www.w3.org/2001/XMLSchema#string

P921

Candida glabrata

P932

2565919

http://www.w3.org/2001/XMLSchema#string